Ensysce Biosciences

Company snapshot

Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses.

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Ensysce Biosciences. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Ensysce Biosciences.

1. Jun 5, 2026 Clinical update

   PF614 capsule — Phase 3

2. Jun 5, 2026 Clinical update

   PF614 capsule — Phase 1

3. May 23, 2026 Clinical update

   PF614 — Phase 2

4. May 23, 2026 Clinical update

   PF614 — Phase 1

5. May 23, 2026 Clinical update

   PF614 — Phase 1

View all clinical trial activity →

• What is Ensysce Biosciences?

  Ensysce Biosciences is a pharma organization headquartered in La Jolla, USA. It trades on NYSE under ticker ENSC. Primary therapeutic focus areas include Acute Pain, Pharmacokinetics, Postoperative Pain, Acute, Recreational Drug Use. NovaPharmaNews links 6 clinical program(s), 0

• Is Ensysce Biosciences publicly traded?

  Yes. Ensysce Biosciences is listed with ticker ENSC on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Ensysce Biosciences develop or market?

  We link 2 drug profile(s) where Ensysce Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ensysce-biosciences#company-drugs.

• What are the latest developments for Ensysce Biosciences?

  In the last 12 months our linked public records show 6 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Ensysce Biosciences focus on?

  Ensysce Biosciences focuses on Acute Pain, Pharmacokinetics, Postoperative Pain, Acute based on our analysis of their pipeline programs and drug development activities.